Fatigue News and Research

RSS

Essilor first quarter revenue increases to €1,027.6 million

Essilor International, the world leader in ophthalmic optics, today announced that consolidated revenue for the three months ended March 31, 2011 totaled €1,027.6 million, an increase of 13.4% over the year-earlier period.

19 Apr 2011

Quest Diagnostics launches AccuType IL28B test for HCV

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, today announced the availability of its AccuType® IL28B test for aiding in the prediction of patient response to peginterferon alpha-based therapy for hepatitis C virus (HCV) infection.

From Quest Diagnostics 18 Apr 2011

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

ImmunoCellular Therapeutics, Ltd., announced that Surasak Phuphanich, MD, Principal Investigator of the Phase I clinical trial of ImmunoCellular's lead dendritic cell cancer vaccine candidate for glioblastoma multiforme presented safety and preliminary efficacy data yesterday at the American Academy of Neurology 63rd Annual Meeting.

16 Apr 2011

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

The U.S. Food and Drug Administration recently approved the NovoTTF-100A System, a new device to treat adults with glioblastoma multiforme that recurs or progresses after receiving chemotherapy and radiation therapy.

15 Apr 2011

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Teva Pharmaceutical Industries Ltd. today announced that several new studies further support the efficacy and safety of the company's innovative central nervous system products.

12 Apr 2011

Study to discover mysterious biological cause of Gulf War Illness

For nearly two decades following the 1991 Gulf War, doctors noticed a trend in many of veterans of that conflict: an unexplainable cluster of symptoms including but not limited to chronic fatigue, memory loss, and depression. It wasn't until 2008 that a scientific panel from the U.S. Department of Veterans Affairs concluded that a third of American troops who served in the Gulf War were suffering from combinations of these symptoms, now recognized collectively as Gulf War Illness (GWI).

12 Apr 2011

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

The Canadian Association of PNH Patients welcomes the upcoming publication of a study that resoundingly proves the efficacy of Soliris, the first and only life-saving treatment for the ultra-rare blood disease known as Paroxysmal Nocturnal Haemoglobinuria.

11 Apr 2011

Childhood cancer survivors' cognitive problems linked to poor sleep and fatigue

A new analysis has found that childhood cancer survivors often suffer from sleep problems and fatigue, which negatively impact their attention and memory. Published early online in Cancer, a peer-reviewed journal of the American Cancer Society, the study indicates that addressing sleep hygiene among survivors of childhood cancer may help to improve their cognitive health.

11 Apr 2011

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Linda Roberts was puzzled when her favorite food, chocolate ice cream, suddenly did not taste good, and her prized orchids didn't smell nice either. When she began having sudden, severe headaches, she mentioned the changes in taste and smell to her doctor. After several tests, Roberts was diagnosed with a glioblastoma multiforme, the most aggressive form of brain tumor.

8 Apr 2011

Persistent fatigue in breast cancer survivors may be caused by autonomic nervous system running in overdrive

The persistent fatigue that plagues one out of every three breast cancer survivors may be caused by one part of the autonomic nervous system running in overdrive, while the other part fails to slow it down.

7 Apr 2011

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

Seattle Genetics, Inc. today announced that data from a case series of Hodgkin lymphoma patients receiving brentuximab vedotin following allogeneic stem cell transplant were presented in an oral session at the European Group for Blood and Marrow Transplantation Annual Meeting in Paris, France.

7 Apr 2011

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

The U.S. Food and Drug Administration today approved vandetanib to treat adult patients with late-stage (metastatic) medullary thyroid cancer who are ineligible for surgery and who have disease that is growing or causing symptoms.

7 Apr 2011

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources.

6 Apr 2011

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

There has been substantial mystery surrounding the origins of Chronic Fatigue Syndrome (CFS), a condition affecting as many as four million Americans and marked by symptoms that include a sense of weariness that sleep does not improve and difficulty with memory and concentration.

6 Apr 2011

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

NorthShore University HealthSystem interventional cardiologist, Ted Feldman, MD, presented positive results from the EVEREST II trial, that were concurrently published in The New England Journal of Medicine.

5 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

The combination of two compounds that inhibit two of the most frequently mutated cancer pathways is showing promise in an ongoing Phase I trial, according to data presented at the AACR 102nd Annual Meeting 2011, held here April 2-6.

4 Apr 2011

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Idera Pharmaceuticals, Inc. announced today the presentation of data from a four-week Phase 1 clinical trial of IMO-2125 in combination with ribavirin in treatment-naïve patients chronically infected with hepatitis C virus genotype 1.

2 Apr 2011

Fatigue News and Research

Essilor first quarter revenue increases to €1,027.6 million

Quest Diagnostics launches AccuType IL28B test for HCV

Data of ImmunoCellular's lead dendritic cell cancer vaccine candidate for GBM presented at AAN meeting

Novocure receives FDA approval for NovoTTF-100A System to treat GBM

Teva presents new CNS products study data in RRMS, Parkinson's at AAN meeting

Study to discover mysterious biological cause of Gulf War Illness

Blood journal to publish Soliris study results in Paroxysmal Nocturnal Haemoglobinuria

Childhood cancer survivors' cognitive problems linked to poor sleep and fatigue

Hope4Cancer offers gentle non-invasive therapies for patients with brain tumor

Persistent fatigue in breast cancer survivors may be caused by autonomic nervous system running in overdrive

Seattle Genetics presents SGN-35 study data in Hodgkin lymphoma at EBMT meeting

AstraZeneca receives FDA approval for vandetanib to treat medullary thyroid cancer

Combination of molecularly targeted cancer drug and anti-malarial drug stops tumor growth

Retrovirus XMRV may not be associated with Chronic Fatigue Syndrome in the central nervous system

The New England Journal of Medicine publishes positive results from NorthShore's EVEREST II trial

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Positive results from GDC-0973, GDC-0941 combination therapy Phase I trial against cancer

Idera's IMO-2125 plus ribavirin Phase 1 trial results against HCV presented at EASL meeting

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News